Physician profile
Priya J Bansal
NPI 1811970486
$1,341,333.06
in general payments reported to CMS, 2019-2025
53 companies · $358K in 2025
The $358K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154K · 2020: $74K · 2021: $136K · 2022: $210K · 2023: $188K · 2024: $220K · 2025: $358K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $442K · Consulting Fee: $196K · Travel and Lodging: $79K · Food and Beverage: $27K · Honoraria: $21K · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $442,380.26 |
| Consulting Fee | $196,226.19 |
| Travel and Lodging | $79,056.18 |
| Food and Beverage | $27,257.77 |
| Honoraria | $21,123.75 |
| Education | $209.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $445,476.56 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Csl Behring | $124,211.77 | 2019-2025 | Andembry, Haegarda, Kcentra |
| Regeneron Healthcare Solutions, INC. | $119,774.76 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $88,678.11 | 2020-2025 | Takhzyro, Eohilia, Cinryze |
| Genzyme Corporation | $85,781.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $77,122.63 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pharming Healthcare, INC. | $54,253.59 | 2019-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $53,214.08 | 2019-2025 | |
| Lilly USA, LLC | $37,645.88 | 2025 | Ebglyss, Taltz |
| Alk-Abello, INC | $37,297.60 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Shire North American Group INC | $36,535.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25,706.07 | 2020-2025 | Airduo Respiclick, Airduo Digihaler, Armonair Digihaler |
| Genentech USA, INC. | $25,690.27 | 2019-2025 | Xolair |
| Amgen INC. | $20,407.99 | 2020-2025 | Tezspire, Actimmune |
| Optinose US, INC. | $19,956.04 | 2019-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $18,403.76 | 2023-2025 | Ayvakit |
| Pfizer INC. | $11,136.17 | 2019-2025 | |
| Incyte Corporation | $9,664.46 | 2022-2025 | Opzelura |
| Ionis Pharmaceuticals, INC. | $8,904.93 | 2025 | Dawnzera |
| F. Hoffmann-La Roche Ag | $8,550.00 | 2023-2025 | |
| Biocryst Pharmaceuticals, INC. | $7,057.69 | 2020-2025 | Orladeyo |
| Jubilant Hollisterstier LLC | $6,292.13 | 2025 | |
| Aquestive Therapeutics, INC. | $5,534.48 | 2025 | |
| Hikma Pharmaceuticals USA | $5,355.58 | 2021-2024 | Ryaltris |
| Regeneron Pharmaceuticals, INC. | $2,946.14 | 2025 | Dupixent |
| Octapharma USA, INC. | $1,589.60 | 2019-2025 | Panzyga, Cutaquig |
| Biocryst US Sales Co., LLC | $664.44 | 2021-2025 | Orladeyo |
| Qol Medical, LLC | $598.54 | 2019-2025 | Sucraid, Sucraid |
| Covis Pharma Gmbh | $495.48 | 2019-2023 | |
| Grifols USA, LLC | $322.15 | 2019-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Hospira, INC. | $316.44 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.92 | 2019-2024 | Spiriva Respimat |
| Bio Products Laboratory USA, INC. | $195.88 | 2019-2023 | Coagadex, Gammaplex |
| Kaleo, INC. | $189.63 | 2019-2024 | Auvi-Q |
| Boston Scientific Corporation | $161.80 | 2023 | Watchman Flx |
| Abbvie INC. | $161.21 | 2023-2025 | Rinvoq |
| Ars Pharmaceuticals Operations, INC. | $158.16 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $137.91 | 2020-2022 | |
| Cycle Pharmaceuticals INC | $66.31 | 2025 | Sajazir |
| Eyevance Pharmaceuticals LLC | $53.67 | 2020-2021 | |
| Adma Biomanufacturing LLC | $52.20 | 2024-2025 | |
| Greer Laboratories, INC. | $49.97 | 2019-2024 | Palforzia |
| Aimmune Therapeutics, INC. | $49.55 | 2021-2023 | |
| Circassia INC. | $43.96 | 2019-2021 | |
| Shockwave Medical, INC | $43.30 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Galderma Laboratories, L.P. | $35.96 | 2025 | Nemluvio |
| Genentech, INC. | $34.34 | 2022-2023 | Xolair |
| Organon LLC | $20.19 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $20.10 | 2023 | |
| Gc Biopharma USA, INC. | $18.41 | 2024 | Alyglo |
| Philips North America LLC | $15.07 | 2019 | |
| Phadia US INC. | $14.25 | 2021 | |
| Horizon Therapeutics Plc | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.